Rates of obesity have climbed over the past few decades and are projected to continue to increase, with severe obesity expected to be the most common body mass index category for women in the coming decade. There are several ways in which weight plays a large role through a woman’s reproductive life, from sex-specific conditions, such as polycystic ovarian syndrome, to changes in her fertility and pregnancy risks, to impacting her well-being during menopause. Management of weight should be patient-centered and include consideration of the patient’s age, other health conditions and medications, and reproductive potential. This review highlights key considerations when treating weight in women patients, including impact on common sex-specific conditions and medications, evidence-based lifestyle counseling, and reproductive considerations of anti-obesity medications.
GwiraJA, FryarCD, GuQ. Prevalence of total, diagnosed, and undiagnosed diabetes in adults: United States, August 2021-August 2023. NCHS Data Brief, 2024(516):CS354814.
WardZJ, BleichSN, CradockAL, et al.Projected U.S. State-Level prevalence of adult obesity and severe obesity. N Engl J Med, 2019; 381(25):2440–2450.
4.
BarberTM, HansonP, WeickertMO, et al.Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health, 2019; 13:1179558119874042.
5.
GaskinsAJ, Rich-EdwardsJW, MissmerSA, et al.Association of fecundity with changes in adult female weight. Obstet Gynecol, 2015; 126(4):850–858.
6.
LemonLS, NaimiAI, AbramsB, et al.Prepregnancy obesity and the racial disparity in infant mortality. Obesity (Silver Spring), 2016; 24(12):2578–2584.
7.
DriscollAK, GregoryECW. Increases in prepregnancy obesity: United States, 2016-2019. NCHS Data Brief, 2020(392):1–8.
8.
MaoL, WangL, BennettS, et al.Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause. Front Physiol, 2022; 13:1043237.
9.
NormanRJ, FlightIH, ReesMC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: Weight and body fat distribution. Cochrane Database Syst Rev, 2000; 2000(2):Cd001018.
10.
CostaGBC, CarneiroG, UmedaL, et al.Influence of menopausal hormone therapy on body composition and metabolic parameters. Biores Open Access, 2020; 9(1):80–85.
11.
KooS, AhnY, LimJY, et al.Obesity associates with vasomotor symptoms in postmenopause but with physical symptoms in perimenopause: A cross-sectional study. BMC Womens Health, 2017; 17(1):126.
12.
CoxME, YancyWS, CoffmanCJ, et al.Effects of counseling techniques on patients’ weight-related attitudes and behaviors in a primary care clinic. Patient Educ Couns, 2011; 85(3):363–368.
13.
SturgissE, van WeelC. The 5 As framework for obesity management: Do we need a more intricate model? Can Fam Physician, 2017; 63(7):506–508.
14.
KleinDA, SylvesterJE, SchveyNA. Eating disorders in primary care: Diagnosis and management. Am Fam Physician, 2021; 103(1):22–32.
15.
VillarealDT, ApovianCM, KushnerRF, et al.; NAASO, The Obesity Society. Obesity in older adults: Technical review and position statement of the American society for nutrition and NAASO, The obesity society. Am J Clin Nutr, 2005; 82(5):923–934.
16.
WilkinsonMJ, ManoogianENC, ZadourianA, et al.Ten-Hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab, 2020; 31(1):92–104.e105.
17.
de CaboR, MattsonMP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med, 2019; 381(26):2541–2551.
18.
JamshedH, BeylRA, Della MannaDL, et al.Early time-restricted feeding improves 24-hour glucose levels and affects markers of the circadian clock, aging, and autophagy in humans. Nutrients, 2019; 11(6):1234.
19.
SuttonEF, BeylR, EarlyKS, et al.Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab, 2018; 27(6):1212–1221.e1213.
20.
MarinacCR, NelsonSH, BreenCI, et al.Prolonged nightly fasting and breast cancer prognosis. JAMA Oncol, 2016; 2(8):1049–1055.
21.
HarrisL, HamiltonS, AzevedoLB, et al.Intermittent fasting interventions for treatment of overweight and obesity in adults: A systematic review and meta-analysis. JBI Database System Rev Implement Rep, 2018; 16(2):507–547.
22.
Services. USDoAaUSDoHaH. Dietary Guideliens for Americans, 2020-2025. ed 9th Edition. Services; 2020.
23.
ConlinPR, ChowD, MillerER, et al.The effect of dietary patterns on blood pressure control in hypertensive patients: Results from the Dietary Approaches to Stop Hypertension (DASH) trial. Am J Hypertens, 2000; 13(9):949–955.
24.
OnwuzoC, OlukorodeJO, OmokoreOA, et al.DASH Diet: A review of its scientifically proven hypertension reduction and health benefits. Cureus, 2023; 15(9):e44692.
25.
DickenSJ, JassilFC, BrownA, et al.Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: A randomized, crossover trial. Nat Med, 2025; 31(10):3297–3308.
26.
HallKD, AyuketahA, BrychtaR, et al.Ultra-Processed diets cause excess calorie intake and weight gain: An inpatient randomized controlled trial of ad libitum food intake. Cell Metab, 2019; 30(1):67–77.e63.
27.
U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans. ed. 2nd Edition. U.S. Department of Health and Human Services; 2018.
28.
GoodpasterBH, DelanyJP, OttoAD, et al.Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: A randomized trial. JAMA, 2010; 304(16):1795–1802.
29.
JohnsDJ, Hartmann-BoyceJ, JebbSA, et al.; Behavioural Weight Management Review Group. Diet or exercise interventions vs combined behavioral weight management programs: A systematic review and meta-analysis of direct comparisons. J Acad Nutr Diet, 2014; 114(10):1557–1568.
30.
RossR, JanssenI, DawsonJ, et al.Exercise-induced reduction in obesity and insulin resistance in women: A randomized controlled trial. Obes Res, 2004; 12(5):789–798.
31.
DonnellyJE, HonasJJ, SmithBK, et al.Aerobic exercise alone results in clinically significant weight loss for men and women: Midwest exercise trial 2. Obesity (Silver Spring), 2013; 21(3):E219–E228.
32.
KingNA, HopkinsM, CaudwellP, et al.Individual variability following 12 weeks of supervised exercise: Identification and characterization of compensation for exercise-induced weight loss. Int J Obes (Lond), 2008; 32(1):177–184.
33.
PolidoriD, SanghviA, SeeleyRJ, et al.How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity (Silver Spring), 2016; 24(11):2289–2295.
34.
JakicicJM, TateDF, LangW, et al.Objective physical activity and weight loss in adults: The step-up randomized clinical trial. Obesity (Silver Spring), 2014; 22(11):2284–2292.
35.
BatsisJA, GillLE, MasutaniRK, et al.Weight loss interventions in older adults with obesity: A systematic review of randomized controlled trials since 2005. J Am Geriatr Soc, 2017; 65(2):257–268.
36.
MitchellWK, WilliamsJ, AthertonP, et al.Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol, 2012; 3:260.
37.
SantanastoAJ, GoodpasterBH, KritchevskySB, et al.Body composition remodeling and mortality: The health aging and body composition study. J Gerontol A Biol Sci Med Sci, 2017; 72(4):513–519.
38.
LentferinkYE, KnibbeCAJ, van der VorstMMJ. Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: A systematic review. Drugs, 2018; 78(18):1887–1901.
39.
LewisKH, FischerH, ArdJ, et al.Safety and effectiveness of longer-term phentermine use: Clinical outcomes from an electronic health record cohort. Obesity (Silver Spring), 2019; 27(4):591–602.
40.
GaddeKM, AllisonDB, RyanDH, et al.Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet, 2011; 377(9774):1341–1352.
41.
GreenwayFL, FujiokaK, PlodkowskiRA, et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2010; 376(9741):595–605.
42.
TorgersonJS, HauptmanJ, BoldrinMN, et al.XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004; 27(1):155–161.
43.
Pi-SunyerX, AstrupA, FujiokaK, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med, 2015; 373(1):11–22.
44.
ChangJJ, LathiRB, KimSH. A retrospective study examining phentermine on preconception weight loss and pregnancy outcomes. Endocr Pract, 2020; 26(9):990–996.
45.
CheshireJ, GargA, SmithP, et al.Preconception and first-trimester metformin on pregnancy outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. Am J Obstet Gynecol, 2025; 233(6):530–547.e8.
46.
TocciV, MirabelliM, SalatinoA, et al.Metformin in gestational diabetes mellitus: To use or not to use, that is the question. Pharmaceuticals (Basel), 2023; 16(9):1318.
47.
WildingJPH, BatterhamRL, CalannaS, et al.; STEP 1 Study Group. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med, 2021; 384(11):989–1002.
48.
JastreboffAM, AronneLJ, AhmadNN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med, 2022; 387(3):205–216.
49.
CarminaE, LongoRA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med, 2023; 12(18):5921.
50.
SkelleyJW, SwearenginK, YorkAL, et al.The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003), 2024; 64(1):204–211.e4.
51.
MinJS, JoSJ, LeeS, et al.A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist. Drug Des Devel Ther, 2025; 19:3509–3537.
52.
CenaH, ChiovatoL, NappiRE. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab, 2020; 105(8):e2695–e2709.
53.
SalamunV, JensterleM, JanezA, et al.Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study. Eur J Endocrinol, 2018; 179(1):1–11.
54.
LiuX, ZhangY, ZhengSY, et al.Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf), 2017; 87(6):767–774.
55.
ImbroaneMR, LeMoineF, NauCT. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am J Obstet Gynecol, 2025; 233(2):116.e1–116.e17.
56.
CestaCE, RotemR, BatemanBT, et al.Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med, 2024; 184(2):144–152.
57.
DiabH, FuquayT, DattaP, et al.Subcutaneous semaglutide during breastfeeding: Infant safety regarding drug transfer into human milk. Nutrients, 2024; 16(17):2886.
58.
HurtadoMD, TamaE, FansaS, et al.Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause, 2024; 31(4):266–274.
59.
WinterJE, MacInnisRJ, WattanapenpaiboonN, et al.BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr, 2014; 99(4):875–890.
60.
EisenbergD, ShikoraSA, AartsE, et al.2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for metabolic and bariatric surgery. Surg Obes Relat Dis, 2022; 18(12):1345–1356.
